maytansine and Brain-Edema

In the last 10 years, multiple new targeted agents have been developed for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Up to 55% of patients with HER2+ breast cancer will develop brain metastases requiring some form of radiation therapy. The interaction between radiation and these targeted agents is unknown and previously unreported.. In this series, we describe 4 patients who developed clinically significant brain edema at sites of treated brain metastases. These patients were treated with stereotactic radiosurgery and trastuzumab emtansine, the newest FDA-approved agent for metastatic HER2+ breast cancer. Additionally, we present rates of clinically significant radiation necrosis among all breast cancer patients treated during this same time period.. Using previously published clinical and preclinical data, we then hypothesize possible mechanisms for this striking interaction.. Increased awareness of potential interactions between targeted agents and radiation to the brain is crucial.

Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Maytansine; Middle Aged; Necrosis; Radiosurgery; Receptor, ErbB-2; Trastuzumab